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Summary 
In the past decade understanding of the role of the Rho GTPases RhoA, 
Rac1 and Cdc42 has been developed from regulatory proteins that 
regulate specific actin cytoskeletal structures – stress fibers, lamellipo-
dia and filopodia – to complex integrators of cytoskeletal structures 
that can exert multiple functions depending on the cellular context. 
Fundamental to these functions are three-dimensional complexes be-
tween the individual Rho GTPases, their specific activators (GEFs) and 
inhibitors (GDIs and GAPs), which greatly outnumber the Rho GTPases 
themselves, and additional regulatory proteins. By this complexity of 
regulation different vasoactive mediators can induce various cytoskel-
etal structures that enable the endothelial cell (EC) to respond ad-
equately. In this review we have focused on this complexity and the 
consequences of Rho GTPase regulation for endothelial barrier func-
tion. The permeability inducers thrombin and VEGF are presented as 
examples of G-protein coupled receptor- and tyrosine kinase receptor-
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mediated Rho GTPase activation, respectively. These mediators induce 
complex but markedly different networks of activators, inhibitors and 
effectors of Rho GTPases, which alter the endothelial barrier function. 
An interesting feature in this regulation is that Rho GTPases often have 
both barrier-protecting and barrier-disturbing functions.  While Rac1 
enforces the endothelial junctions, it becomes part of a barrier-disturb-
ing mechanism as activator of reactive oxygen species generating 
NADPH oxidase. Similarly RhoA is protective under basal conditions, 
but becomes involved in barrier dysfunction after activation of ECs by 
thrombin. The challenge and promise lies in unfolding this complex 
regulation, as this will provide leads for new therapeutic opportunities. 
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1. Introduction 
During the late 1990s evidence accumulated that the small GTPase 
RhoA plays an essential role in many vascular pathologies includ-
ing hypertension, vasospasm and vascular leakage (1–4). Although 
RhoA was known to regulate many cellular processes including 
F-actin cytoskeleton and microtubule (MT) dynamics, cell polar-
ity, gene regulation, as well as cell-cycle progression, it remained 
unclear how alterations in activity of this single molecule could 
lead to such diverse (biological) activities (5, 6). Soon it became 
clear that a close interplay between RhoA and other members of 
the Rho GTPase family contribute to the fine-tuning of the bio-
logical effects of Rho GTPase activation. Rho GTPases belong to 
the Ras superfamily of proteins. So far, at least 20 members of the 
Rho superfamily have been identified (4, 7, 8). The best-studied 
members of the Rho GTPase family are RhoA, Rac1 and Cdc42. 
They contribute to many aspects of cell behaviour, such as cell mi-
gration, cell division and contraction (5). This is reflected in a var-
iety of biological processes, such as axon growth, leukocyte infil-
tration and angiogenesis (5, 6). For example, regulation of en-
dothelial barrier integrity, which is disrupted in many vascular pa-
thologies, not only involves RhoA, but also Rac1 and Cdc42 
(9–12). Additionally, it was recognised that the individual Rho 
GTPases can exert both positive and negative effects on the en-
dothelial barrier integrity, depending on their cellular context and 
mode of (pathological) activation, adding an additional level of 
complexity to fine-tuning of the biological response (13, 14).  
To date, it has been generally accepted that the combined ac-
tions of the Rho GTPases require a crucial spatio-temporal regu-
lation of their activities. This regulation, which involves over 150 
regulatory proteins, plays a significant role in many vascular pa-
thologies. However, knowledge regarding the contribution of indi-
vidual regulatory proteins to vascular dysfunction is still fragmen-
tal. Yet it is here, where a new area for specific therapeutic targeting 
opens up.  
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In this review we discuss the principles of regulation of Rho 
GTPase activity in vascular function. We focus on barrier dysfunc-
tion by the hyperpermeability inducers thrombin and vascular 
endothelial growth factor-A (VEGF) as main representatives of 
G-protein coupled receptor (GPCR)- and receptor tyrosine ki-
nase (RTK)-mediated Rho GTPase activation, respectively. After a 
short introduction about the role of Rho GTPases in regulation of 
the endothelial barrier and the nature of the regulatory proteins 
involved, we first describe the regulation of Rho GTPases during 
endothelial barrier maintenance. Next, we describe thrombin-
mediated Rho GTPase signalling, which results mainly in a con-
tractility and inter-endothelial gap formation. This is followed by 
a discussion of VEGF-induced Rho GTPase regulation, which dis-
rupts the junctional complexes and causes actin cytoskeleton rear-
rangement required for endothelial migration. Finally, we briefly 
discuss Rho GTPase regulation during permeability induced by 
other agents and indicate some future perspectives. 
Ligand-dependent Rho GTPase regulation involved in 
barrier dysfunction 
The F-actin cytoskeleton plays a major role in the maintenance of 
the endothelial barrier function, as it determines cell shape, facili-
tates cell adhesion to the sub-endothelial matrix, and participates 
in regulation of junctional complexes. The dynamics and structure 
of the F-actin filaments are mainly regulated by the Rho GTPases 
RhoA, Cdc42 and Rac1 (7, 11). In addition, during barrier main-
tenance the regulation of Rac1 activity also involves the Rap 
GTPase Rap1 (15). Several vasoactive agents, like β-adrenergic 
agonists, sphingosine-1-phosphate (S1P) (16, 17), and adrenome-
dullin (18), improve the endothelial barrier integrity by enforcing 
the dense peripheral F-actin band. This process involves changes in 
the activities of several Rho GTPases. The activities of RhoA, Rac1, 
Cdc42 and Rap1 are not only involved in regulating barrier main-
tenance, but also in active enforcement and disruption of barrier 
integrity. Other vasoactive agents, such as thrombin and VEGF, can 
mediate barrier dysfunction via the regulation of often the same 
Rho GTPases, but activated in another context within the cell. 
A reconstruction of the time courses of thrombin- and VEGF-
mediated alterations in Rho GTPase activities based on several EC 
studies is shown in Figure 1 (17, 19–23). It is clear that the time 
course – and for Rac1 also the direction – of the activity changes are 
different after activation by these mediators. The profound in-
crease of RhoA induced by thrombin is primarily involved in stress 
fiber (SF) formation and cell contraction, whereas VEGF-regu-
lated Rho GTPases cause protrusions and cell migration. Simulta-
neously thrombin also weakens the junctional complexes by indi-
rectly inhibiting Rac1 and relocating Cdc42 (20). In vitro as well as 
in vivo this results in a hyperpermeable endothelial monolayer 
(24). In vitro the delayed activation of Rac1 and Cdc42 restores the 
endothelial barrier after approximately two hours by initiating cell 
junction reassembly (20). In contrast, the combined activity 
changes of Rac1, Cdc42 and RhoA induced by VEGF cause cell 
protrusion and migration (5). Unlike thrombin, VEGF induces 
rapid activation of Rac1 and the therewith-coupled generation of 
reactive oxygen species (ROS), leading to endothelial barrier dys-
function (25–27). VEGF-mediated activation of Cdc42 and RhoA 
is involved in SF formation (28). These data thus show ligand-de-
pendent regulation of the Rho GTPases, and indicate that Rho 
GTPases under different conditions can have distinct biological ef-
fects. This points to contextual activation of downstream targets. 
Regulation of Rho GTPase activities  
To appreciate the role of Rho GTPases in health and disease it is 
necessary to understand how they are regulated. GTPases cycle be-
tween an active, GTP-bound state and an inactive, GDP-bound 
state (Fig. 2). The activation of Rho GTPases requires guanine 
Figure 1: Time profiles 
of RhoA, Rac1 and 
Cdc42 GTPase activ-
ities after stimulation 
of endothelial cells by 
thrombin (left) and 
VEGF (right). Solid lines 
represent reported Rho 
GTPase activities, dotted 
lines represent extra-
polated GTPase activities 
(17, 19–23).  
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nucleotide exchange factors (GEFs) that catalyse the exchange of 
GDP for GTP in the switch regions of the Rho GTPase. Inacti-
vation of Rho GTPases is mediated by GTPase activating (GAP) 
factors. The type of nucleotide (GDP or GTP) that is bound at the 
switch region of the GTPase determines the conformation of the 
switch region as well as the GTPase activity. Furthermore, guanine 
dissociation inhibitors (GDIs) subsequently keep Rho GTPases in 
their inactive state (see below). For more detailed information 
about small GTPase signalling and their domain functions we refer 
to Siderovski & Willard (29) and Rossman et al. (30), respectively. 
Here, we highlight some characteristics that are important to 
understand the function of RhoA, Rac1 and Cdc42 in the regu-
lation of permeability. 
Activation of Rho GTPases by guanine nucleotide 
 exchange factors (GEFs) 
The human genome contains at least 83 GEFs that fall into two dis-
tinctive families (31). The first is the diffuse B-cell lymphoma 
(Dbl)-family. Members of this family contain a Dbl homology 
(DH) domain followed by a pleckstrin homology (PH) domain. 
The DH domain mediates RhoGEF activity, while the PH domain 
has an auto-inhibitory role (30–33). The PH domains of these 
typical RhoGEFs interact with phospholipids and may therefore 
localise the GEF and subsequent GTPase activation to the mem-
brane. A specific subgroup of these RhoGEFs provides a structural 
motif known as regulator of G-protein signalling (RGS) domain, 
by which they can form molecular complexes with Gα12/13 units of 
GPCRs. This interaction accelerates the GTPase activity of Gα12/13 
Figure 2: Regulation 
of GTPases Rap1, Rac1, 
RhoA and Cdc42 by 
currently known GAPs 
(blue) and GEFs (red) 
during barrier main-
tenance (C) and throm-
bin (T)- or VEGF (V)-
mediated endothelial 
permeability. * Indi-
cates G-protein binding 
GEFs, - indicates negative 
regulation. (For a list of 
all currently known Rho-
GEFs and RhoGAPs we 
refer to supplemental 
data of Sanz-Moreno et 
al. (37). Thrombin also 
activates Ras GTPases, 
see (38).  
5- to 10-fold, thus enhancing the signal-to-noise ratio of RhoA ac-
tivation by Gα proteins. Known members of this sub-group (* in 
Fig. 2) are leukemia-associated RhoGEF (LARG, also known as 
ARHGEF12), p115RhoGEF (also known as GEF1 and ARHGEF1) 
and PDZ-RhoGEF (also known as GTRAP48 and ARHGEF11) 
(29, 34–36).  
The second typical RhoGEF family is the DOCK-family. This 
family lacks DH and PH domains. RhoGEF activity is instead me-
diated by DOCK homology region (DHR) 1 and 2 domains (39). 
DOCK-family members activate either Rac1 or Cdc42 (39–41). To 
date no member of this family has been associated with RhoA ac-
tivation. 
There are several mechanisms for GEF activation. The first is by 
phosphorylation. It has e.g. been shown that protein kinase Cα 
(PKCα) activates p115RhoGEF via a serine phosphorylation (25, 
42), while tyrosine phosphorylation of PDZ-RhoGEF and LARG 
was shown by focal adhesion kinase (FAK) (42, 43). More impor-
tantly, GEFs can be activated by RTKs via Src and adaptor proteins. 
Of the 58 human RTKs, more than half are known to activate at 
least one of 16 RhoGEFs in addition to activating their common 
signal transduction pathways via phosphatidylinositol 3-kinase 
(PI3K), phospholipase C (PLC) and the mitogen-activated protein 
kinase (MAPK) pathways (44).  
Finally, activation of GEFs may be dependent on their subcellu-
lar localisation. This mechanism is known to regulate the spatio-
temporal activation of RhoA and Rac1. Examples are ECT2 and 
Net1 (also known as ARHGEF8 and NET1A). These are nuclear 
RhoGEFs, but their translocation to the cleavage furrow and the 
plasma membrane, respectively, has been associated with RhoA ac-
tivation (45, 46). In addition, the activation of Rac1 was associated 
with plasma membrane localization of the cytosolic RhoGEF 
Tiam1 (30, 47). The RhoGEF GEF-H1 (also known as ARHGEF2, 
GEF, p40, LFP40) interacts with MTs and is involved in the cross-
talk between the MT- and actin-network (48, 49). MT interaction 
inhibits its GEF activity for RhoA at the plasma membrane, but al-
ternatively may switch its GEF specificity towards Rac1 (30, 50).  
Inactivation of Rho GTPases by GTPase activating 
proteins (GAPs) 
The second group of molecules to regulate Rho GTPase activity are 
the GAPs. In contrast to what their name suggests, Rho GTPases 
have a relatively slow intrinsic GTPase activity. GAPs enhance the 
GTP hydrolysis of the active GTPases thereby causing inactivation 
of these proteins (Fig. 2). To date, more than 70 RhoGAPs have 
been identified. Interestingly, at least one of them, p73RhoGAP, 
has a preferential endothelial expression (51, 52), but expression of 
most GAPs is ubiquitous. Similar to RhoGEFs, RhoGAPs are also 
regulated by extracellular cues, such as growth factors. 
Several mammalian RhoGAPs have been implicated in specific 
Rho GTPase-mediated biological functions such as angiogenesis, 
migration, cell blebbing and endocytosis. As nicely surveyed by 
Tcherkezian and Lamarche-Vane (53), studies of the past decade 
have shed some light on the question why the RhoGAPs out-
number Rho GTPases by 2- to 3-fold (53, 54). Probably more im-
portant than tissue-specificity, is that GAPs, but also GEFs, may se-
lectively regulate a specific downstream signalling pathway by acti-
vating Rho GTPase activities when they are in complex with other 
proteins, thereby leaving other GTPases and their pathways unal-
tered. Some RhoGAPs seem to specifically act on a single Rho 
GTPase, whereas others display activity towards multiple Rho pro-
teins, explaining why Rho activities simultaneously rise or fall. Fur-
thermore, RhoGAPs may act as scaffold molecules independent of 
their GAP activity, mediating cross-talk between Rho GTPases and 
other signalling pathways. In addition to GAP and GEF domains, 
these Rho GTPase regulatory proteins often also have docking sites 
for other proteins so that they integrate signals from different 
pathways thereby directing specific downstream signalling.  
Rho GTPase regulations by guanine nucleotide 
 dissociation inhibitors (GDIs) 
During nucleotide exchange GTP is preferentially bound to Rho 
GTPases because intracellular levels of GTP are substantially 
higher than those of GDP. GDIs interact with the switch domains 
of Rho GTPases to prevent activation by GTP and lock Rho 
GTPases in their inactive state. Furthermore, GDIs retain inactive 
GTPases in the cytosol by shielding off their membrane tag (30). 
There are currently three RhoGDIs known. RhoGDIα (also known 
as RhoGDI-1, Rho-GDIα, RABGD1A and RABGDIA) is ubiqui-
tiously expressed, whereas RhoGDIβ (also known as D4, Gdid4, 
Ly-GDI, ArhGDIβ) is expressed in haematopoetic cells and RhoG-
DIγ (also known as Rho-GDI3 and ARHDIAG) is preferentially ex-
pressed in organs and the brain, where it is anchored to the mem-
brane (55, 56). Although the mechanisms are still largely un-
known, RhoGDIs seem to regulate the fine-tuning of Rho GTPase 
activities via their association with multiprotein complexes in par-
ticular membrane microenvironments (55, 56). 
2. Basal maintenance of the endothelial 
 barrier 
Initial attention for Rho GTPases was drawn to RhoA activation 
and its role in cell contraction and endothelial hyperpermeability 
(see section 3). During the last years the focus has moved to the role 
of Rac and Cdc42 in the assembly and stability of inter-endothelial 
junctions (20, 57). Furthermore, an additional role for RhoA and 
its effector Rho kinase in barrier maintenance was recognised (20). 
Both tight junctions (TJs) and adherens junction (AJs) con-
tribute to the intercellular sealing of the endothelial monolayer 
and the resulting endothelial barrier function. In contrast to 
blood-brain ECs, in which the TJs form a sealing belt, TJs in most 
other ECs have a mosaic structure leaving space for the passage of 
macromolecules. The AJs contribute largely to the barrier proper-
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ties of these latter endothelia in interaction with the actin cytos-
keleton (Fig. 3).  
Proteins and assembly of AJs 
Much attention has been given to the regulation of AJs and their pi-
votal protein VE-cadherin, a membrane spanning protein that 
forms homotypic interactions between adjacent ECs (25) (Fig. 3, 
right panel). The intracellular part of VE-cadherin is connected to 
the F-actin cytoskeleton via both α-and β-catenin (25). In addi-
tion, a third catenin, p120catenin (p120ctn), binds to VE-cadher-
in (58). P120ctn binding to VE-cadherin is an important step in 
the regulation of AJ stabilisation as well as in Rho GTPase regu-
lation.  
Rac1 and Cdc42 are activated at sites where junctional com-
plexes are formed (59, 60), while RhoA activity is downregulated 
when the monolayer reaches confluence (61). Indeed, Rac1-defi-
cient ECs are unable to form lamellipodial structures, focal ad-
hesions and cell-cell contacts (62). Furthermore, many GTPase 
regulator activities are directly initiated by cadherin engagement 
(see below). Thus, a precise spatial and temporal fine-tuning of the 
activity of Rho family GTPases is critically important in the estab-
lishment and maintenance of junctions. 
Another AJ protein is the endothelial-specific HEG (heart of 
glass) transmembrane receptor (Fig. 3, right panel), which inter-
acts with an as yet unknown extracellular ligand to activate a coor-
dinated signalling response through inhibiting the activity of 
RhoA. This response requires the cerebral cavernous mal-
formations proteins CCM1 (or KRIT1), CCM2 and CCM3 (63) 
and leads to a cellular response that may include induction of en-
dothelial vacuolisation and homotypic endothelial cell-to-cell 
junction formation. These cellular events are required for normal 
vascular development and maintenance of vascular integrity. De-
fects in these steps result in enhanced activation of RhoA and may 
lead to the pathological changes associated with hereditary cer-
ebral cavernous malformations in humans (64, 65). Loss of RhoA 
degradation, which is achieved by the ubiquitin ligase (E3) 
Smurf-1, after interaction with CCM2 is accompanied by in-
creased endothelial permeability (66, 67). Deletion of CCM2 did 
not affect the Rac1 concentration in ECs (66).  
Interaction of junctional proteins with Rho GTPases 
Concerning basal endothelial barrier regulation, much attention 
has been given to the relationship between VE-cadherin, the cate-
nins and Rho GTPases. After cadherin engagement p120ctn bind-
Figure 3: Rho GTPase activity regulates barrier integrity. The major TJ 
and AJ protein interactions are indicated in the right box. On the left side part 
of an AJ is enlarged. Here, cadherin engagement with the catenins via Vav2 
activates Cdc42 and Rac1. VE-cadherin bound p120ctn and Rac1 inhibit 
RhoA by activation of p190RhoGAP. Via PAK1-mediated inhibition of 
p115RhoGEF Rac1 activity further suppresses RhoA. Linking of the junctional 
complex to the actin cytoskeleton stabilizes the AJs and further inhibits RhoA 
by activation of GRAF2. Enhanced levels of cAMP induce Rap1-mediated 
Rac1 activation as well as RhoGDI-mediated inhibition of RhoA. For further 
details see text. 
ing activates Vav2, a GEF for Cdc42 and Rac1 (68, 69) (Fig. 3, left 
panel). This GEF positively regulates Cdc42 and Rac1 activity. Both 
GTPases bind IQGAP (IQ motif containing GTPase-activating 
protein 1). Unlike the name suggests IQGAP1 does not have GAP 
activity, meaning that it does not enhance the GTP hydrolytic ac-
tivity of the GTPases. Instead its binding to Cdc42 and Rac1 in-
hibits their intrinsic GTPase activity, thus keeping them in their ac-
tive, GTP-bound state (70–72). By recruiting IQGAP1, Rac1 and 
Cdc42 inhibit the interaction of IQGAP1 with β-catenin thereby 
initiating the binding of α- and β-catenin (20, 73). This cross-links 
the complex with the actin cytoskeleton and stabilises the AJ (74). 
In contrast, inactivation of Rac1 and Cdc42 causes dissociation 
from IQGAP1 that then binds to β-catenin at the AJ complex. As a 
result α- and β-catenin dissociate, leading to weaker adhesion and 
inter-endothelial gap formation (75).  
It is likely that similar mechanisms also occur at the TJ level. Re-
cently, data revealed that in epithelial cells RICH1 (also known as 
ARHGAP17), which has GAP activity for Cdc42 is required for the 
stability of epithelial TJs. In vivo the TJ component and scaffolding 
protein angiomotin binds RICH1. This suppresses its GTPase ac-
tivity, thus allowing Cdc42-mediated barrier protection (76).  
RhoA activity and gap closure 
Consistent with previous data in other cells (77), we recently found 
that in non-stimulated EC monolayers RhoA activity, as measured 
by Raichu-FRET, occurs prior to gap closure (unpublished data). 
The inactivation of RhoA upon gap closure was explained by bind-
ing of p120ctn to the newly formed AJ complex, which causes 
p120ctn-mediated activation of p190RhoGAP and thus inacti-
vation of RhoA (58, 78) (Fig. 3, left panel).  
Another molecular mechanism has been described that reduces 
RhoA activity upon establishment of AJs. ARHGAP10 (also 
known as GRAF2) in vitro inactivates RhoA and Cdc42 (53). In 
vivo human GRAF2 inhibits RhoA and recruits α-catenin to the 
newly formed cell-cell contacts (79) (Fig. 3), thereby stabilising the 
AJs.  
Inactivation of RhoA by Rac1 
Under confluent conditions, cAMP stimulates Epac which has GEF 
activity for Rap1 (15). Rap1 initiates the activation of Vav2 result-
ing in active Rac1 (80). Activated Rac1 further inactivates RhoA by 
several downstream targets (Fig. 3). Rac1 subsequently activates 
p190RhoGAP thereby inhibiting RhoA (58). Furthermore, Rac1 
activates its downstream target PAK1, which inhibits p115Rho-
GEF, thus further repressing the activity of RhoA (24, 81). In addi-
tion, enhanced cAMP levels activate protein kinase A (PKA), which 
stimulate RhoGDI binding – and thus further inactivation – of 
RhoA (82).  
An additional pathway for Rap1 activation was shown upon 
VE-cadherin engagement with β-catenin (Fig. 3). The membrane-
associated guanylate kinase with inverted domain structure-1 
(MAGI-1), which links via β-catenin to VE-cadherin (83, 84), 
binds RapGEF2 (also known as PDZ-GEF1, RA-GEF, NRAPGEP, 
Rap-GEP and CNrasGEF) (84). The subsequently activated Rap1 
recruits vinculin from cell-matrix to cell-cell contacts (83). Vincu-
lin supports the linking of α-catenin to α-actinin, thereby further 
stabilising VE-cadherin-based cell adhesion (85). Rap1 thus not 
only mediates the activation of Rac1 but also promotes the stabili-
sation of VE-cadherin based junctions. 
Finally, it has been suggested that activation of Rac1, which is 
accompanied by the release of RhoGDIα, induces the inhibition of 
RhoA activity by increasing the interaction of RhoA with the newly 
released RhoGDIα (86).  
Summing up 
In conclusion, the maintenance of the endothelial barrier depends 
on RhoA, Cdc42 and Rac1 activation. RhoA activity decreases 
upon gap closure due to VE-cadherin and p120ctn engagement. 
The binding of the AJs to the actin cytoskeleton involves Cdc42, 
which is kept in its active state by binding to IQGAP1. The linking 
of the AJs to the actin cytoskeleton also activates GRAF2, which in-
hibits RhoA. The rise in cAMP levels, via PKA, activates RhoGDIα 
thereby inhibiting RhoA. In addition, rising cAMP levels and cad-
herin engagement induce the activation of Epac and RapGEF2, re-
spectively. These GEFs stimulate Rap1, which via Vav2 activates 
Rac1. Rac1 activation results in the inhibition of p115RhoGEF and 
thus a suppression of RhoA. Vav2 activity is further enhanced by 
p120ctn binding to the junctional complexes. The latter also di-
rectly activates p190RhoGAP thereby further inhibiting RhoA ac-
tivity.  
3. Receptor-mediated cell activation by 
thrombin 
One of the best-studied activators of RhoA in the context of en-
dothelial permeability regulation is thrombin. Thrombin mediates 
its effect on RhoA directly via its receptor PAR-1 (87, 88). Throm-
bin-mediated cleavage of PAR-1 activates several heterotrimeric 
G-proteins and their subsequent signalling pathways. The release 
of the α-subunits of these G-proteins (Gα11/Q, Gα12/13 and Gαi) 
regulates the activity of RhoA (35, 89–91) and Rac1 (15, 80), either 
directly (35, 91), or via intracellular Ca2+ (35, 89, 91) or cyclic ade-
nosine monophosphate (cAMP) elevation (15, 80, 82, 90). As re-
cently shown, knockdown of Gα11/Q or Gα12/13 in human ECs pre-
vents RhoA activation by thrombin (92, 93), indicating that both 
pathways are highly interrelated at the level of RhoA activation and 
together control downstream signalling leading to EC contraction 
and permeability.  
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Direct and indirect (in) activation of Rho GTPases by 
thrombin 
In the following chapter we survey the thrombin-mediated acti-
vation of RhoA, which involves several pathways and is associated 
with SF formation and cell contraction. Next, we discuss how 
thrombin may prolong RhoA activity. Furthermore, it is explained 
how thrombin initially causes an inhibition of Rac1, which is im-
plicated in weakening of the junctional complexes, while later, a 
delayed recovery of both Rac1 and Cdc42 activities results in en-
dothelial barrier recovery.  
G-protein-mediated activation of RhoA by thrombin  
Thrombin-mediated cell contraction requires two pathways that 
are interrelated at the level of RhoA activation (Fig. 4). The first 
pathway involves thrombin-mediated activation of Gα11/Q, which 
causes coupling to phospholipase Cγ (PLCγ) that in turn generates 
inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 via its 
receptor on the endoplasmic reticulum (ER) liberates Ca2+ from 
the ER. This Ca2+ release activates calmodulin (CaM), which phos-
phorylates myosin light chain kinase (MLCK) resulting in en-
hanced myosin light chain (MLC) phosphorylation (Thr18 and 
Ser19) (94–96). Increased MLC phosphorylation enhances acto-
myosin interactions (97), cell contraction and permeability (98). 
Meanwhile DAG activates the transient receptor potential channel 
(TRPC)-6 at the plasma membrane, which allows for Ca2+ influx 
from the extra-cellular matrix and activation of PKCγ (99). PKCγ 
has a dual role. It directly mediates the inhibitory phosphorylation 
(Ser96) of RhoGDIα (100, 101) and the stimulatory phosphory-
lation of p115RhoGEF (91, 101). This causes RhoA liberation and 
activation, respectively. 
The second pathway involves the thrombin-mediated activation 
of Gα12/13, which binds and activates p115RhoGEF, thus resulting in 
activated RhoA (34, 102). Via its downstream target Rho kinase, 
RhoA directly enhances SF formation and cell contraction. Rho ki-
nase induces the phosphorylation of the regulatory subunit MYPT1 
(Thr691 and Thr855) of the myosin light chain phosphatase 
(MLCP) (103). This decreases the phosphatase activity of MLCP, 
thereby reducing the de-phosphorylation of MLC (13, 104). Rho ki-
nase by itself also can phosphorylate MLC (Ser19) (105). Thereby 
further enhancing MLC phosphorylation, which leads to acto-myo-
sin interactions as described above. 
Feedback mechanisms prolonging RhoA activation 
Several positive feedback mechanisms can prolong the activation 
of RhoA and the subsequent cell contraction (Fig. 4). Via the mem-
Figure 4: Thrombin-
mediated regulation of 
Rho GTPases involves 
several G-protein- 
activated pathways. 
For details see text. The 
inhibitory effects of Rac1 
on RhoA activity are 
 discussed in section 3 
“Modulation of Rac1 
 activity by thrombin” and 
depicted in  Figure 3. 
brane localised TRPC-1, RhoA further increases the Ca2+ influx 
(25) that prolongs the Gα11/Q-mediated activation of MLCK, 
PKCα and RhoA. Three additional feedback pathways involve Rho 
kinase signalling. First, Rho kinase phosphorylates ezrin (Thr567), 
radixin (Thr564) and moesin (Thr558), which are collectively 
known as the ERM-proteins (106). ERM phosphorylation en-
hances SF formation thereby stimulating cell contraction and en-
dothelial permeability. Second, it was shown for endothelin-
1-stimulated vascular smooth muscle cells that Rho kinase causes 
an inhibitory phosphorylation (Ser1150) of p190RhoGAP (also 
known as ARHGAP5, GRLF1, GRF-1) (107) of which two iso-
forms, p190A and p190B, are known. The first is associated with 
prolonging RhoA activation (107). As prolonged RhoA activation 
is also seen during thrombin stimulation, it is likely that Rho ki-
nase-mediated p190A inhibition also occurs during thrombin 
stimulation of ECs. Third, thrombin/p115RhoGEF-mediated acti-
vation of Rho kinase induces MT disassembly. This activates 
GEF-H1, a RhoA specific GEF that is known to localise at the MTs 
(48, 49). In its MT-bound state, the guanosine-exchange activity of 
GEF-H1 is suppressed, whereas GEF-H1 released from MTs stimu-
lates GEF activity and may thus induce further activation of RhoA 
(48).  
In addition to Rho kinase, RhoA also activates protein kinase 
C-related kinase (PRK or PKN), which can regulate FAK-mediated 
focal adhesions. Rho kinase and PRK-mediated activities are both 
required for full thrombin-induced EC hyperpermeability (92). 
Accumulating evidence suggests a dual, time-dependent role for 
FAK in the regulation of thrombin-mediated RhoA activity: 
Thrombin-mediated FAK phosphorylation occurs after 5 minutes 
(min) and peaks after 10 min (43). Approximately 3–5 min after 
thrombin stimulation Gα12/13-mediated FAK activation results in 
an activating phosphorylation of PDZ-RhoGEF and LARG, which 
causes prolonged RhoA activity (43). Subsequently, 10 min after 
thrombin stimulation FAK activates p190RhoGAP (108), which in 
vivo preferentially inhibits RhoA activity (108–110). This time 
course of p190RhoGAP phosphorylation coincides with the de-
crease in RhoA activity both in human pulmonary artery and um-
bilical vein ECs (21, 108). Thus, thrombin-mediated FAK acti-
vation in ECs first extends and then down-regulates the activation 
of RhoA (see to Suzuki et al. (111) for more detail about inter-
actions between Gα12/13 proteins and their RhoGEFs). 
Finally, thrombin stimulates RhoA activity by activating Gαi. 
The Gαi inhibits adenyl cyclase (AC), which reduces cAMP levels 
in vascular smooth muscle cells (112) and in ECs (90, 113). Via at-
tenuation of PKA this causes a reduced RhoGDIα activity thereby 
allowing further activation of RhoA (82).  
Modulation of Rac1 activity by thrombin 
As indicated before, thrombin-mediated endothelial permeability 
in vitro also involves a one hour-lasting inactivation of Rac1 (93). 
This is thought to weaken the junctional complexes, which in com-
bination with cell contraction, results in enhanced endothelial per-
meability. Several thrombin-mediated pathways may be involved 
in the inhibition of Rac1 (Fig. 4). First, it is known that the PAR-
1/Gαi-mediated inhibition of AC, which decreases cAMP levels 
(90, 113) causes the inhibition of Rac1 (93), a process that involves 
the inhibition of the RapGEF Epac and Rap1 (80) (see section 2 
“Inactivation of RhoA by Rac1”). Second, in tumor cells the RhoA/
Rho kinase-mediated acto-myosin interaction inhibits Rac1 via 
the activation of the usually vascular specific ARHGAP22 (also 
known as RhoGAP2) (37). Third, Rho kinase activates the vascular 
specific FILGAP, a longer isoform of p73RhoGAP (also known as 
ARHGAP24 and RC-GAP72), which also antagonises Rac1 (51). 
Although no data is available on thrombin-mediated ARHGAP22 
or FILGAP regulation in ECs, it has been shown that this Rho-me-
diated inhibition of Rac1 regulates amoeboid movement, which 
depends on Rho/Rho kinase signalling (37, 51). It seems likely that 
thrombin signalling also causes ARHGAP22 and FILGAP acti-
vation. It is of interest to note that suppression of Rac1, indirectly 
enhances p115RhoGEF activity thus further stimulating RhoA ac-
tivation (24).  
Thrombin not only inhibits Rac1, but occasionally may also 
cause a delayed Rac1 activation by indirect mechanisms. In mouse 
pulmonary ECs thrombin-mediated activation of PKCα leads to 
the activation of sphingosine kinase that catalyses the formation of 
S1P from sphingosine, thereby causing paracrine activation of the 
S1P receptor (17). Subsequently, Gαi-activated PKCε induces 
phospholipase D2 activation and enhanced Rac1 activity in vascu-
lar smooth muscle cells (114). Delayed thrombin-mediated acti-
vation of Rac1 stabilises newly formed junctional complexes and 
enhances the endothelial barrier integrity (20, 73, 93). Rac1 activ-
ity increases during junction formation (10, 60). In contrast to 
other authors, Diebold et al. (115) reported a rapid increase in ac-
tive Rac1 15 min after thrombin stimulation. This increase, which 
was accompanied by activation of NADPH oxidase, occurred indi-
rectly via phosphodiesterase 2. 
For more details about the role of Rac1 in maintaining the en-
dothelial barrier integrity see section 2 “Interactions of junctional 
proteins with Rho GTPase”.  
Cdc42 modulation by thrombin 
Besides Rac1 Cdc42 participates in recovery of the endothelial bar-
rier integrity. Thrombin stimulation of ECs quickly causes the re-
localisation, but not inactivation (116), of Cdc42 from the plasma 
membrane to the cytosol (93). This basal Cdc42 activity seems to 
contribute to the correct thrombin-induced acto-myosin contrac-
tion and SF formation (117). Delayed Cdc42 activation coincides 
in time with the activation of Rac1 (1 hour after thrombin stimu-
lation) (93). Cdc42 additionally, is involved in Golgi-derived 
membrane trafficking (118, 119). The cycling of Cdc42 between 
the active and inactive form seems essential for its function in pro-
tein transport and polarity. Cdc42 at the Golgi occurs via PX-
RICS, a splicing variant of RICS (also known as p250RhoGAP, 
p200RhoGAP and Grit), which is expressed in a wide variety of 
cells and has GAP activity for Cdc42. In HeLa cells PX-RICS inter-
acts with β-catenin and regulates the ER-to-Golgi transport of the 
N-cadherin/β-catenin complex (120). In epithelial cells the E-cad-
herin recycling to the membrane is regulated by both Rac1 and 
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Cdc42 and takes place prior to p120catenin binding to the junc-
tional complexes (see section 4) (121).  
Summing up 
By activation of its receptor PAR-1 thrombin mediates activation 
of RhoA via Gα11/Q-, Gα12/13- and Gαi-mediated pathways. The 
availability of RhoA for activation is enhanced by Gα11/Q/Ca2+/ 
PKCα/- and Gαi/cAMP/PKA-mediated RhoGDIα inhibition. 
The activation of RhoA is induced by Gα11/Q/Ca2+/PKCα and 
Gα12/13(FAK)-activated RhoGEFs (p115RhoGEF, LARG and 
PDZ-RhoGEF). Subsequent inactivation of RhoA is mediated by 
FAK-activated p190(A)RhoGAP. Thrombin stimulation further 
inhibits Rac1, partially by decreased cAMP levels and partially due 
to Rho kinase-mediated activation of FILGAP and acto-myosin 
interaction-induced activation of ARHGAP22. Finally, thrombin 
causes a delayed activation of both Rac1 and Cdc42. Cdc42, which 
at the Golgi is activated by PX-RICS, stimulates the transport of 
junctional proteins towards the plasma membrane, thereby caus-
ing the repair of the junctional complexes.  
Consequences for the regulation of permeability 
Infusion of thrombin receptor activating peptide, which mimics 
the action of thrombin, was shown to induce pulmonary micro-
vascular permeability in situ (122). Its infusion into the hindleg of 
a heparinised rat causes a rapid swelling due to increased endothe-
lial permeability (unpublished data). Endothelial permeability in-
duction by thrombin in endothelial cell monolayers in vitro has ex-
tensively been used to study mechanisms underlying permeability 
regulation (123). This enhancement occurs in a biphasic way. In-
itially a rapid drop in transendothelial electrical resistance occurs 
accompanied by a moderate increase in permeability for macro-
molecules like albumin and peroxidase. This is accompanied by 
Rac1 inhibition and Cdc42 translocation, which facilitate loosen-
ing of the AJs. Together with the thrombin-induced activation of 
tyrosine kinases like Src (21, 25), which by phosphorylational 
changes reduces the homotypic interaction between junctional 
proteins (98, 124), this causes the disruption of the AJs (125). At 
the same time RhoA/Rho kinase activity together with 
Ca2+/MLCK activity enhance actin-myosin interaction, induce SFs 
and cause a general cell contraction. The latter mechanism causes 
a second phase of a further increased hyperpermeability, which 
starts 10–15 min after thrombin exposure and ceases after 60 min, 
when Rac1 and Cdc42 activities also normalise again. Overall this 
second phase leads to inter-endothelial gap formation and cell 
rounding. While cell contraction was already implied in early 
studies on endothelial permeability in vivo (126), the extent of con-
traction and leakage in vitro seems disproportional as compared to 
the situation in vivo. In situ thrombin stimulation of arteriolar and 
venular ECs indeed leads to cell contraction and cell rounding, but 
the inter-endothelial gaps are clearly smaller (127). In ECs in vivo 
RhoA/Rho kinase activation only leads to a contraction at the cell 
margins, which is nonetheless enough to cause vascular leakage 
(128). An increasing amount of evidence suggests that this appar-
ent difference in degree of cell contraction is at least partially due to 
the flexibility of the underlying tissue.  
Interestingly RhoA/Rho kinase activity, which is present at the 
cell margins, disappears after thrombin stimulation, while then, 
Rho kinase activity at the SFs becomes visible (127). This local de-
crease at the cell margins, together with altered local activities of 
Rac1 and Cdc42 mentioned above, point to potential roles of Rho 
GTPases in the formation and maintenance of junctional com-
plexes and endothelial barrier function. 
Finally, when primed e.g. during the late phase of sepsis or upon 
activation with activated protein C, PAR1 switches from being a 
vascular-disruptive receptor to a vascular-protective receptor, a 
phenomenon that might involve transactivation of PAR2 and S1P 
receptor-1 (129–131). This ‘role reversal’ of PAR-1 is accompanied 
by a dampening of RhoA activation and recovery of Rac-GTP lev-
els. 
4. VEGF receptor-mediated activation 
 involved in permeability  
VEGF-mediated endothelial permeability is complex and involves 
the formation of transendothelial pores through the fusion of en-
dothelial vesicles and disruption of endothelial junctions. Though 
the precise mechanisms are still unclear, Rho GTPases are also in-
volved in this latter aspect of VEGF-mediated permeability (11). 
Compared to thrombin, VEGF-mediated Rho GTPase activation 
appears more restricted to a direct effect on the disruption of the 
AJs. 
ECs express two VEGF receptors that recognise VEGF-A, 
known as VEGFR1 (also known as Flt-1) and VEGFR2 (known as 
Flk1 and KDR). They belong to the family of receptor tyrosine ki-
nases (RTKs). Though during embryogenesis both receptors are 
involved, in adult ECs VEGFR2 is in particular involved in activat-
ing ECs during angiogenic processes. Upon binding to VEGF, 
VEGFR2 undergoes dimerisation and oligomerisation, which acti-
vates its intrinsic tyrosine kinase activity resulting in auto- and 
trans-phosphorylation on specific tyrosine residues in the cyto-
plasmic domain (132). These tyrosine residues, when phosphory-
lated, are docking sites for Src homology 2 (SH2) binding domain 
containing downstream effectors. For more detailed information 
on VEGFR2 phosphorylation see Olsson et al. (133).  
Under confluent conditions in vitro and in vivo, VE-cadherin 
interacts with VEGFR2 (10,134) in an IQGAP1-mediated manner 
(135). While the number of these complexes increase upon VEGF 
stimulation (135), VEGF, in a Rac1-dependent manner, leads to 
vascular permeability (26, 136). VEGF-mediated RhoA and Cdc42 
activation are involved in cytoskeleton rearrangements needed for 
cell migration (22), a process that requires binding of activated 
VEGFR2 to the αvβ3 integrin (137).  
VEGF/RTK-mediated Rac1 activation and ROS 
generation 
During activation by VEGF, the VEGFR2 is phosphorylated on 
multiple tyrosine residues, including Tyr951, Tyr1175, Tyr1212 
and Tyr1214. While Tyr1175 is essential for PLCγ-mediated 
ERK1/2 activation and DNA synthesis (138), and Shb-mediated 
focal adhesion formation (133), Tyr1212, Tyr1214, and probably 
Tyr951, are involved in activation of Rho GTPases.  
As a result of VEGF-induced phosphorylation of VEGFR2 
(Tyr1212) Src is activated (139). Within 3 min this stimulates Vav2, 
Rac1 and its downstream target PAK1 (23, 140). PAK1 phosphory-
lates VE-cadherin (Ser665) inducing the recruitment of β-arres-
tin2 and the internalisation of VE-cadherin into clathrin-coated 
vesicles (141) (Fig. 5). Deletion of Rac1 in vitro in primary ECs in-
deed decreased VEGF-mediated endothelial permeability (62). 
This observation contrasts to other observations that Rac is 
required for the generation of the endothelial barrier under basal 
conditions (59, 60, 62). This suggests different modes of action of 
Rac1 in regulating endothelial permeability.  
VEGF-activated Rac1 can also activate NADPH oxidase at the 
EC membrane. Indeed, in human pulmonary microvascular ECs it 
was demonstrated that VEGF-mediated activation of Rac1 caused 
ROS generation that was inhibited by a NADPH oxidase inhibitor 
(26). This activation was accompanied by an increase in endothe-
lial permeability, which was based on the phosphorylation of 
Tyr658 and Tyr731 of VE-cadherin, which cause detachment of 
p120ctn and β-catenin, respectively, and phosphorylation of 
Tyr654 on β-catenin. Inhibition of either Rac1 or NADPH oxidase 
activity prevented the increase in endothelial permeability and the 
accompanying phosphorylations of VE-cadherin. Whether ROS 
act directly on the kinase activity, or, more likely, inhibit VE-cad-
herin associated tyrosine phosphatases, has still to be clarified. Fur-
thermore, the phosphorylations of VE-cadherin may occur con-
textually. It is unknown whether phosphorylation of VE-cadherin 
at Tyr658 and Tyr731 will occur simultaneously with that of Ser665 
or that they exclude each other mutually. Similarly, the phosphory-
lation of Tyr685 of VE-cadherin may affect the other phosphory-
lations (142).  
ROS production is apparently an essential component in sig-
nalling cascades that mediate Rac1/p190RhoGAP-induced down-
regulation of RhoA (27). ROS production causes p190RhoGAP 
translocation to the AJs, where it binds p120ctn, and subsequently 
inhibits local RhoA activity (58). It thus plays a role in the stabili-
zation of cell-cell contacts (Fig. 5). A regulatory role in this process 
was shown for IQGAP1, which upon VEGF stimulation is rapidly 
(<5 min) recruited to VEGFR2. This is associated with tyrosine 
phosphorylation of IQGAP1 and subsequent binding and acti-
vation of Rac1. In addition, it causes further VEGFR2 association 
with the VE-cadherin/β-catenin complex (135). Deletion of 
IQGAP1 indeed decreases Rac1-mediated ROS production and 
prevents cell migration and proliferation (135, 143).  
Additional effects of VEGF/RTK on RhoGTPases 
In addition to the Tyr1212 phosphorylation, phosphorylation of 
the adjacent Tyr1214 on VEGFR2 causes binding and activation of 
heat-shock protein 90 (HSP90). HSP90 indirectly mediates the ac-
tivation of RhoA and subsequently Rho kinase, which, as described 
above, leads to acto-myosin interaction and cell contraction (144). 
Rho kinase also phosphorylates FAK (Ser732). This specific phos-
phorylation is a crucial step for subsequent additional phosphory-
lations of FAK by Src (144) and Shb (144, 145), which are crucial 
for paxillin and vinculin recruitment to the focal adhesion sites 
(144).  
The transient Tyr1214 phosphorylation of VEGFR2 fur-
thermore recruits and activates the adapter protein Nck, which 
triggers the Src family kinase Fyn, indirectly (maybe via PAK2) re-
sulting in Cdc42 activation (144). Cdc42 targets PAK1 which turns 
on SAPK2 (stress-activated protein kinase 2) belonging to the 
family of p38 MAPK (144, 146). Via SAPK2 signalling the actin-
polymerization factor HSP27 is activated, thereby further increas-
ing SF formation (28, 144) (Fig. 5). HSP90/RhoA-dependent phos-
phorylation of FAK is required for this Cdc42/SAPK2-mediated SF 
formation (144). The overexpression of Cdc42GAP indeed in-
hibited endothelial migration (147).  
Interestingly, in tumor ECs lacking associated pericytes VEGF-
mediated Tyr951 phosphorylation of VEGFR2 binds TSAd (T-cell-
specific adapter molecule) which is required for SF formation and 
motility (133), suggesting that this pathway is involved in RhoA ac-
tivation. Although the cross-linking of RTK and GPCR signalling 
lies outside the scope of this review, we like to mention that VEGF-
induced phosphorylation of VEGFR2 at Tyr951 also mediates acti-
vation of RhoA and Rac1 via the Gα11/Q and Gβγ subunits (19) 
(Fig. 5). Additionally, VEGF-induced G-protein coupled PLCβ3 
activation regulates migration of ECs and vascular sprouting by 
activation of Cdc42 (148).  
Gα12/13 seems not to be involved in the cross-linking of RTK and 
GPCR signalling, which may explain why activated RhoA levels are 
much lower in VEGF-activated ECs than in thrombin-stimulated 
ECs (22). The different levels of RhoA activation may underlie 
functional differences between thrombin and VEGF signalling. 
Thrombin stimulates a generalised contraction of ECs, whereas 
VEGF-mediated migration involves retraction of the trailing edges 
of the cells, which nonetheless can lead to inter-endothelial gap 
formation (22).  
VEGF-induced Rho GEFs and GAPS 
Several Rho GTPase regulating proteins have been identified that 
are involved in VEGF-induced vascular responses in animal mod-
els. VEGF was shown to activate the RhoA-specific GEF ECT2 via 
the actin binding protein Kleip, a process that is further stimulated 
under hypoxia due to up-regulation of Kleip (149). Since Kleip/
ECT2 is required for cell migration (149), it seems reasonable to 
hypothesise that Kleip/ECT2 forms part of the HSP90-mediated 
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RhoA activation pathway (Fig. 5). In addition, the angiomotin/
RICH1 complex, which stabilises the TJs by maintaining Cdc42 ac-
tivity (76), upon VEGF stimulation recruits the RhoGEF Syx, 
which mediates local RhoA activity (150, 151). Syx has been en-
countered in ECs in vivo (150, 151). 
Rho kinase activity and the RhoA/Rho kinase-mediated acto-
myosin interaction cause activation of FILGAP (p73RhoGAP) and 
ARHGAP22, respectively. In HUVECs overexpression of p68Rac-
GAP (the mouse equivalent of human ARHGAP22) indeed in-
hibited Rac1-dependent lamellipodia formation and cell mi-
gration (152). Although not much is known about it, contraction-
mediated inhibition via p73RhoGAP and ARHGAP22 may explain 
the dip in the VEGF-mediated Rac1 activation after 5 min (see Fig. 1). 
One may anticipate that these endothelial GAPs and GEFs also 
play a role in the regulation of VEGF-mediated permeability. 
Summing up 
VEGF/VEGFR2-mediated activation of Rac1 involves Vav2 and 
mediates VE-cadherin phosphorylation and internalisation. 
Meanwhile, Rac1 is also activated in a VEGFR2/IQGAP1-mediated 
manner, leading to ROS production. This results in tyrosine phos-
phorylation of VE-cadherin, subsequent detachment of β-catenin 
and p120ctn, and increased permeability. ROS also induces a 
p190RhoGAP/p120ctn-mediated inactivation of RhoA. Cdc42 is 
further activated by VEGF-mediated inhibition of Cdc42GAP and 
VEGR2-phosphorylation. In the latter pathway PAK2 may be in-
volved as a GEF for Cdc42. VEGF/VEGFR2/HSP90-mediated acti-
vation of RhoA occurs possibly via activation of Kleip and ECT2 
and is involved in cell migration. In addition, RhoA activation by 
Syx occurs at the cell margins and is involved in protrusion 
formation. VEGF-mediated Rho/Rho kinase-activated p73Rho-
GAP, supported by the acto-myosin interaction-activated ARH-
GAP22, subsequently inhibits Rac1. And finally, VEGF-mediated 
activation of RhoA, Rac and Cdc42 was shown in a G-protein-me-
diated manner.  
5. Rho GTPases in permeability regulation 
by other agents  
Many other vascular mediators, such as platelet activating factor 
(153), hydrogen peroxide (154), oxidized LDL (155), bacterial to-
xins (156), TNFα (2), lysophosphatidic acid (LPA) (157), angio-
poietins (158, 159) and also leukocytes can modulate Rho GTPase-
Figure 5: VEGF-mediated GTPase regulation induces endothelial per-
meability. VEGFR2 can be phosphorylated at multiple tyrosine sites of which 
three are indicated. Tyr1212 phosphorylation of VEGFR2 induces Rac1-me-
diated VE-cadherin internalisation and endothelial permeability. VEGF 
further induces Rac1-mediated ROS production, which via VE-cadherin phos-
phorylation at Tyr658 and Tyr731 induces the disassembly of p120ctn and 
β-catenin, respectively. ROS-mediated p190RhoGAP recruitment to the AJs 
locally inhibits RhoA. Rac1 thus dually mediates permeability and adhesion. 
Phosphorylation of Tyr1214 mediates RhoA and Cdc42 activation needed for 
acto-myosin interactions and SF formation. Finally, Tyr951 phosphorylation 
induces crosslinking to G-protein-mediated activation of Rho GTPases. It is 
likely that TSAd is involved in this process. For further detail see text.
mediated inter-endothelial gap formation. GTPase regulation by 
TNFα and LPA involves known but also new GEFs and GAPs.  
Little is known about the Rho GTPase regulation by LPA in the 
endothelium. From other cell types it is known that, like thrombin, 
LPA mediates a FAK-dependent activation of RhoA via PDZ-Rho-
GEF (160, 161). In addition, LPA enhances the expression of Net1, 
which positively effects RhoA activity and cell migration (162). 
The RhoA effector mDia was furthermore shown to associate with 
LARG thereby forming a positive feedback mechanism for LPA-
mediated RhoA activity (163). It is unknown whether these path-
ways also play a role in thrombin-mediated RhoA activation. The 
same is true for LPA-mediated activation of p116-Rho-interacting 
protein (p116RIP), a RhoA specific GAP (164) that simultaneously 
binds RhoA and MYPT1, the regulatory subunit of MLCP. This 
way LPA activates MLCP and simultaneously inhibits RhoA, thus 
dually suppressing acto-myosin interaction and cell contraction 
(165).  
Like thrombin, TNFα induces RhoA-mediated SF formation, 
cell contraction and endothelial permeability (2). Unlike thrombin, 
TNF-induced GEF-H1-mediated RhoA activation, was shown 
downstream of TNFα-induced ERK signalling (166). Furthermore, 
TNFα induces the expression of interleukin (IL)-6 and IL-8. This 
involves TNFα-mediated Rac1 activation, which modulates p68, a 
subunit of the transcription factor NF-κB (167, 168). To date how-
ever, it is not known how this Rac1 activity is regulated. TNFα sig-
nalling involves factor-associated-with-nSMase (FAN), an adaptor 
protein that links the plasma membrane to the actin cytoskeleton. 
FAN is a key mediator of TNFα-induced Cdc42 activation and filo-
podia formation (169). The RhoGEF that links FAN to Cdc42 acti-
vation has not yet been identified. 
Angiopoietins recently have drawn a lot of attention as modi-
fiers of endothelial barrier function through modulation of Rho 
GTPase activity (158, 159), as was reviewed by van der Heijden et 
al. (159). Angiopoietins are growth factors known to function as li-
gands for the RTK Tie2. Angiopoietin (Ang)-2 provokes inflam-
mation and vascular hyperpermeability, while Ang-1 has a protec-
tive effect. The ratio of the circulating levels of Ang-1 and Ang-2 
strongly associates with pulmonary microvascular permeability in 
diseases such as ARDS (159). Ang-2 inhibits phosphorylation of 
the Tie2 receptor, which increased RhoA and Rho-kinase activity 
(158). In contrast, Ang-1-induced Tie2 receptor phosphorylation, 
which signals via PI3-kinase and Rac1 to activate p190RhoGAP 
(159). Alternatively, Ang-1 might act by promoting the activation 
of mDia through RhoA, resulting in the association of mDia with 
Src. This deprives VEGFRs of an essential molecule required for 
the disruption of endothelial cell-cell contacts and paracellular 
permeability (14). This barrier-protective effect of RhoA through 
mDia is in apparent contrast to the response of e.g. thrombin and 
LPS, which enhance vascular permeability through a robust and 
persistent RhoA activation and the consequent Rho kinase-de-
pendent assembly of SFs and cell contraction. The strength and lo-
cation of RhoA activation may therefore affect the choice of the 
RhoA downstream target, thereby determining whether RhoA-
initiated signals protect the barrier function of ECs or promote 
vascular leakage.  
Finally, leukocyte activation of the ECs induces clustering of 
ICAM-1. This stimulates the Rho specific SGEF, which activates 
the small GTPase RhoG (170). The dorsal ruffles that are sub-
sequently formed assemble a docking structure around the leuko-
cyte and enable leukocyte migration throught the EC monolayer. 
In addition to SGEF, the Rho/Rac GEF Trio may also be activated 
downstream of ICAM-1 clustering, since it associates to filamin. 
6. Conclusion and perspectives  
Rho GTPases, which were discovered as regulatory proteins that 
regulate specific actin cytoskeletal structures – SF by RhoA, lamel-
lipodia by Rac1 and filopodia by Cdc42 – are now known as com-
plex integrators of cytoskeletal structures that can have multiple 
functions depending on the cellular context. Fundamental to these 
functions are three-dimensional complexes between the individu-
al Rho GTPases, their specific GEFs and GAPs, which largely out-
number the Rho GTPases themselves, and additional regulatory 
proteins. By this complexity of regulation different vasoactive 
mediators can induce various cytoskeletal structures that enable 
the ECs to respond adequately. In this review we have focused on 
the consequences of Rho GTPase regulation for endothelial barrier 
function.  
From the foregoing discussion it has become clear that GPCR- 
and RTK-mediated activations of Rho GTPases have markedly dif-
ferent effects. The G-protein coupled thrombin receptor PAR-1 in-
duces mainly RhoA-mediated cell rounding, whereas RTK 
VEGFR2, by means of VEGF, induces protrusion, cell migration 
and angiogenesis. Thus the initial idea to investigate Rho GTPase 
signalling in order to find a therapeutic target to counteract per-
meability seems logical. However, we have seen here that many dif-
ferent and even independent pathways lead to thrombin-mediated 
activation of RhoA. Moreover, there are several pathways that in-
dependently result in the stimulation of different Rho GEFs and 
GAPs, suggesting that targeting just one of them is not going to ef-
ficiently inhibit RhoA activation and permeability. 
In contrast, VEGF-mediated Rho GTPase regulation shows that 
the fine-tuning of RhoA, Rac1 and Cdc42 activities drives different 
processes at the same time. The spatio-temporal regulation is cru-
cial here and may thus form an interesting opportunity to interfere 
with one process while stimulating another.  
An interesting feature of Rho GTPases in endothelial barrier 
regulation is that they often have both barrier protecting and bar-
rier disturbing functions. While Rac1 in most conditions enforces 
the junctions that form the endothelial barrier, it becomes part of 
a barrier disturbing mechanism as activator of NADPH oxidase, 
which generates ROS. Similarly RhoA has a dual role in barrier 
regulation, being protective in basal conditions, but strongly in-
volved in barrier dysfunction after activation of ECs by thrombin. 
At present most information on Rho GTPases has been ac-
quired from studies in cultured cells. Cultured ECs display certain 
characteristics more pronounced than their in vivo counterparts, 
e.g. the extent of SF formation, while other aspects are more domi-
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nant in vivo. Future studies have to clarify the importance of vari-
ous parts of the signalling pathways in pathological conditions in 
vivo. Both studies in transgenic animals and evaluation of clinical 
samples are needed to assemble the insight needed for pharmaco-
logical intervention in man. In this context, location-specific 
GTPase regulators, preferably EC-specific GEFs and GAPs, may be 
the most interesting to modulate the formation of cell protrusions 
and migration or endothelial permeability. The challenge today is 
to unfold their regulation, thereby not only looking at the GTPase 
for which they have the highest GEF or GAP affinity, but also deter-
mining their effect on the other GTPases since it is this cross-talk, 
or the lack of it, that makes them an interesting therapeutic target. 
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